Vimta Labs Ltd
Vimta Labs Q1 FY26 earnings call: Revenue & Margins
Q1 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Vimta Labs expects healthy growth, targeting a 15% to 20% CAGR, which is about double the industry growth rate. Vimta Labs aims to achieve an annual revenue run rate of INR 120-125 crores by end of the current year, targeting INR 500 crore annually.
From Vimta Labs Ltd's Q1 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Vimta Labs expects healthy growth, targeting a 15% to 20% CAGR, which is about double the industry growth rate.
- The company aims to double its turnover within the next 3 years based on current and planned capex.
- Growth drivers include pharmaceutical services (preclinical, clinical research, cGMP analytical), electrical and electronics testing (a sunrise industry), and biologics contract research and development services expected to commercialize from Q1 FY 2027.
- Export revenue, mainly from pharmaceutical services, is growing strongly and expected to sustain.
- Expansion in laboratory infrastructure will support organic growth for the next 5 years without need for additional space.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Vimta Labs Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- FY '26 planned capex: INR 80-100 crores, with INR 26 crores already spent in Q1 FY '26.
- Approximately 30% of FY '26 capex is earmarked for biologics contract research and development services setup.
- Remaining capex aims at purchasing new equipment and replacing existing equipment.
- Past capex majorly spent on new facility construction (over INR 60 crores in previous year).
- Investments also focused on digitizing and automating laboratory processes.
- New facility infrastructure created to support organic growth for the next 5 years.
2 more points management made on capital expenditure plans
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Vimta Labs Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The clinical trial pipeline is described as "quite encouraging" with a decent number of inquiries received in the last quarter.
- A couple of clinical trial projects are in the final stages of conversion, with others also looking promising.
- The company is focusing on building a track record in clinical trials, which is a new area for them.
- No specific numeric order book or pending order values are disclosed in the transcript.
- Overall demand across sectors including pharma, food, and electronics is positive.
2 more points management made on order book & pipeline
Vimta Labs Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹109 Cr, net profit ₹21 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Vimta Labs Ltd's management said in earlier quarters
- Q3 FY25 earnings call analysis →
- Q1 FY27 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
- Q4 FY23 earnings call →
- Q3 FY23 earnings call →
Others in Healthcare Services this season
- Aster DM Quality (Q1 FY26)
Recent quarters saw subdued volume growth due to leadership changes and seasonal effects, but an 8% volume growth was achieved in Q1 FY26, improving from 2% in…
- Dr Agarwal's Hea (Q1 FY26)
70 crores via preferential allotment to AEHL for CAPEX plans, particularly the flagship facility at Cathedral Road, indicating capacity and service…
- Syngene International Ltd (Q1 FY26)
Operating EBITDA grew 21% YoY in Q1 FY '26 with margins rising to ~24% from 22% last year. Key concall takeaways from Syngene International Ltd's Q1 FY26…
- Yatharth Hospit. (Q1 FY26)
International patient business is growing but will remain around 10% of revenue, positively impacting ARPOB without hurting margins. Key concall takeaways from…
Frequently Asked Questions
What were Vimta Labs Ltd Q1 FY26 results?
Vimta Labs expects healthy growth, targeting a 15% to 20% CAGR, which is about double the industry growth rate. Vimta Labs aims to achieve an annual revenue run rate of INR 120-125 crores by end of the current year, targeting INR 500 crore annually.
What is Vimta Labs Ltd share price analysis?
Vimta Labs Ltd currently shows a neutral. The stock trades at a P/E of 34.1 with a market cap of ₹2,757 Cr. Investors should review the full earnings analysis for detailed insights.
Is Vimta Labs Ltd planning capital expenditure?
FY '26 planned capex: INR 80-100 crores, with INR 26 crores already spent in Q1 FY '26.
Keep Vimta Labs Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.